X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ELDER PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ELDER PHARMA DISHMAN PHARMA/
ELDER PHARMA
 
P/E (TTM) x 25.1 -0.2 - View Chart
P/BV x 3.3 0.1 3,316.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ELDER PHARMA
Jun-14
DISHMAN PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs374380 98.5%   
Low Rs129188 68.6%   
Sales per share (Unadj.) Rs197.8491.2 40.3%  
Earnings per share (Unadj.) Rs21.2-3.2 -666.5%  
Cash flow per share (Unadj.) Rs34.714.4 241.0%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.9376.5 47.8%  
Shares outstanding (eoy) m80.6920.54 392.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.6 220.0%   
Avg P/E ratio x11.9-89.3 -13.3%  
P/CF ratio (eoy) x7.219.7 36.8%  
Price / Book Value ratio x1.40.8 185.5%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3065,833 348.1%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3552,179 245.8%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96110,089 158.2%  
Other income Rs m265257 103.4%   
Total revenues Rs m16,22610,346 156.8%   
Gross profit Rs m4,103-792 -518.1%  
Depreciation Rs m1,091361 301.9%   
Interest Rs m9442,756 34.3%   
Profit before tax Rs m2,334-3,653 -63.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m624125 498.3%   
Profit after tax Rs m1,711-65 -2,618.4%  
Gross profit margin %25.7-7.8 -327.5%  
Effective tax rate %26.7-3.4 -780.0%   
Net profit margin %10.7-0.6 -1,655.1%  
BALANCE SHEET DATA
Current assets Rs m11,0189,240 119.2%   
Current liabilities Rs m9,5179,998 95.2%   
Net working cap to sales %9.4-7.5 -125.2%  
Current ratio x1.20.9 125.3%  
Inventory Days Days11046 238.6%  
Debtors Days Days3560 58.1%  
Net fixed assets Rs m16,30410,124 161.0%   
Share capital Rs m161206 78.5%   
"Free" reserves Rs m12,9075,582 231.2%   
Net worth Rs m14,5167,734 187.7%   
Long term debt Rs m4,1894,889 85.7%   
Total assets Rs m29,80522,882 130.3%  
Interest coverage x3.5-0.3 -1,067.0%   
Debt to equity ratio x0.30.6 45.7%  
Sales to assets ratio x0.50.4 121.5%   
Return on assets %8.911.8 75.8%  
Return on equity %11.8-0.8 -1,395.0%  
Return on capital %17.522.3 78.6%  
Exports to sales %24.83.0 815.7%   
Imports to sales %3.70.4 874.6%   
Exports (fob) Rs m3,956307 1,290.3%   
Imports (cif) Rs m59643 1,383.5%   
Fx inflow Rs m4,952307 1,615.0%   
Fx outflow Rs m697125 556.1%   
Net fx Rs m4,255181 2,346.8%   
CASH FLOW
From Operations Rs m2,78611,754 23.7%  
From Investments Rs m-1,529-561 272.8%  
From Financial Activity Rs m-941-6,762 13.9%  
Net Cashflow Rs m3164,432 7.1%  

Share Holding

Indian Promoters % 61.4 39.6 155.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 7.5 49.3%  
FIIs % 12.7 16.8 75.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 36.1 61.2%  
Shareholders   46,261 16,479 280.7%  
Pledged promoter(s) holding % 35.8 77.6 46.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Where Will the Two-Faced Market Go from Here?(Podcast)

The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

Feb 4, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)

Feb 5, 2019

A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Do You Have the Stomach to Survive a Small Cap Crash?(Profit Hunter)

Feb 5, 2019

While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS